Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer

Oncologist

Volumn 11, Issue SUPPL. 1, 2006, Pages 4-12

  Baselga, José ^a   Perez, Edith A ^b   Pienkowski, Tadeusz ^c   Bell, Richard ^d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b MAYO CLINIC   (United States)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Andrew Love Cancer Centre   (Australia)

Author keywords

Adjuvant; Clinical trial; Early breast cancer; HER 2 positive; Trastuzumab

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EARLY CANCER; FOLLOW UP; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERSTITIAL PNEUMONIA; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HEART DISEASE; HEART STROKE VOLUME; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HEART DISEASES; HUMANS; MULTICENTER STUDIES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; STROKE VOLUME;

EID: 33846064604     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-90001-4     Document Type: Conference Paper

References (15)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
3. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274.
4. Osoba D, Slamon DJ, Burchmore M et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20:3106-3113.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
6. Baselga J, Carbonell X, Castañeda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-2171.
7. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
9. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
10. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94(suppl 1):S5.
11. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
12. Perez EA, Suman VJ, Davidson N et al. NCCTGN9831. May 2005 update. Slide presentation at the 41st American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 13-17, 2005. Available at http://www.asco.org/ac/1,1003,
13. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABPB-31. J Clin Oncol 2005;23:7811-7819.
14. Perez EA, Suman VJ, Davidson NE et al. Interim cardiac safety analysis of NCCTGN9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol (Meeting Abstracts) 2005;23:17s.
15. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111.